Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)

The CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on
patient education, support and research. Dedicated to addressing the unmet needs of the (CLL) chronic lymphocytic leukemia and
related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials,
support and build patient networks, engage in research and educate providers and patients.

What’s New in CLL?

  • Watch Dr. Adrian Warnock of Blood Cancers Uncensored interview our own Dr. Brian Koffman.
  • Dr. Danilov discusses New Drug Targeting SYK Pathway Provides Hope When Used in Combination with Obinutuzumab
  • Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2). Read more.
  • In this interview, Dr. Choi discusses updates contained in an abstract he presented at ASH 2019 entitled: Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness and Its Combination with Ibrutinib is Safe and Effective: Planned Analysis of the CirII Phase 1/2 trial for CLL and MCL.
  • The CLL Society is pleased to share our published research from the European Hematology Association Annual Congress, IMPACT OF CLL SOCIETY’S (CLLS) FREE EXPERT ACCESS PROGRAM (EAP) FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS (PTS).

CLL Society Expert Access™

Access to a CLL expert is critical to ensure receiving the best possible care and has proven to improve survival. In partnership with Verastem Oncology (Expert Access Founding Supporter), Genentech, and InfiniteMD, the CLL Society is proud to offer this free second opinion program for CLL patients.

Get Started

We Are in this Together

1 Comment

Comments are closed.